Cited by 244Sirtuins and Resveratrol in MedicineNeurological Disorders and TreatmentsBiochemical and Molecular Research

P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage

Open access
Wang, Gelin, Han, Ting, Nijhawan, Deepak, Theodoropoulos, Pano, Naidoo, Jacinth, Yadavalli, Sivaramakrishnan, Mirzaei, Hamid, Pieper, Andrew A. +2 more·2014·Cell

Abstract

The P7C3 class of aminopropyl carbazole chemicals fosters the survival of neurons in a variety of rodent models of neurodegeneration or nerve cell injury. To uncover its mechanism of action, an active derivative of P7C3 was modified to contain both a benzophenone for photocrosslinking and an alkyne for CLICK chemistry. This derivative was found to bind nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme involved in the conversion of nicotinamide into nicotinamide adenine dinucleotide (NAD). Administration of active P7C3 chemicals to cells treated with doxorubicin, which induces NAD depletion, led to a rebound in intracellular levels of NAD and concomitant protection from doxorubicin-mediated toxicity. Active P7C3 variants likewise enhanced the activity of the purified NAMPT enzyme, providing further evidence that they act by increasing NAD levels through its NAMPT-mediated salvage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2014.07.040

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SBI-797812 had a limited effect of boosting only hepatic NAD+ levels in vivo.

    “Despite the limited effect of SBI-797812 of boosting only hepatic NAD+ levels in vivo”
  • P7C3 enhances NAMPT activity and boosts NAD+ levels in doxorubicin-treated human cells.

    “the neuroprotective agent P7C3 enhances NAMPT activity and boosts NAD+ levels in doxorubicin-treated human cells”
  • SBI-797812 is a potent NAMPT activator active in the nanomolar range; it increased NAMPT-mediated NMN production in vitro and NAD+ levels in cell lines and in vivo.

    “SBI-797812, was proposed as a potent NAMPT activator active in the nanomolar range. This compound increased NAMPT-mediated NMN production in vitro and, importantly, NAD+ levels in cell lines and in vivo214,215.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 37 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S., Mirzaei, H., Pieper, A. A., Ready, J. M., & McKnight, S. L.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • University of Iowa (US)
Corresponding author
  • Ready, Joseph M.
  • McKnight, Steven L.
Venue
Cell
Publisher
Elsevier BV
Published
2014-09
Volume
158
Issue
6
Pages
1324-1334
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2155395152
Cited by
243
References
37
Citations by year
2026: 10 · 2025: 16 · 2024: 17 · 2023: 18 · 2022: 20 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 31 · 2017: 22 · 2016: 25 · 2015: 20 · 2014: 4
FWCI
12.06
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R01MH087986, 5-R01-MH087986)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
neuroprotection, visfatin, NAD+ salvage pathway, NAD+ depletion, doxorubicin toxicity, neurodegeneration, enzyme activation
MeSH terms
Animals, Carbazoles, Cells, Cultured, Doxorubicin, Humans, NAD, Neurons, Cytokines, Neuroprotective Agents, Cell Line, Tumor, Mice, Metabolic Networks and Pathways, Nicotinamide Phosphoribosyltransferase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review